COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND Russian patent published in 2022 - IPC A61K35/17 A61K31/454 A61P35/00 

FIELD: immunotherapy.

SUBSTANCE: treatment method includes the administration of T-cell therapy to a subject with cancer, where T-cell therapy includes genetically engineered T-lymphocytes expressing a chimeric antigen receptor (CAR), which is specifically binds to an antigen related to cancer; and the administration to a subject of an immunomodulator compound, which relieves degradation of Ikaros (IKZF1) and/or Aiolos (IKZF3), where the beginning of the administration of the specified immunomodulator compound is performed at least two days after the beginning of the administration of T-cell therapy. Another option of the treatment method is also disclosed.

EFFECT: group of inventions provides for increased or improved activity, efficiency, persistency, reproduction and/or proliferation of T-lymphocytes for adoptive cell therapy or endogenous T-lymphocytes recruited by immunotherapeutic agents.

80 cl, 40 dwg, 6 tbl, 18 ex